Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,064 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Cystic Clear all
Terminated Not applicable Interventional Results available

Cystic Fibrosis and Urinary Incontinence

NCT04922255
View directory record Official record
Conditions
Urinary Incontinence, Cystic Fibrosis
Interventions
Reusable Underwear, Disposable urethral support, Pelvic floor physical therapy
Device · Behavioral
Lead sponsor
Megan Bradley
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2024 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Acoustic Waveform Respiratory Evaluation

NCT06512064
View directory record Official record
Conditions
Asthma, COPD, Cystic Fibrosis, Ciliary Motility Disorders, Bronchiectasis, Airway Malacia, Healthy Control
Interventions
AWARE
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
8 Years to 70 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
2
States / cities
Indianapolis, Indiana • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed No phase listed Observational

Early Detection of Pancreatic Cystic Neoplasms

NCT02110498
View directory record Official record
Conditions
Pancreatic Cysts, Intraductal Papillary Mucinous Neoplasm, Pancreatic Mucinous-Cystic Neoplasm, Cystic, Mucinous and/or Serous Neoplasm, Solid Pseudopapillary Tumour of the Pancreas
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional

Open-Label Phase III Long-Term Safety Trial of Liprotamase

NCT00449904
View directory record Official record
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
Liprotamase
Drug
Lead sponsor
Anthera Pharmaceuticals
Industry
Eligibility
7 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
39
States / cities
Oakland, California • Denver, Colorado • Jacksonville, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Not applicable Interventional

International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

NCT01464606
View directory record Official record
Conditions
Pleuropulmonary Blastoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Ifosfamide, Doxorubicin
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
Up to 21 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional

Feasibility of a Goal-based Agenda Setting Intervention

NCT04696484
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Disease
Interventions
coopeRATE Prompt
Behavioral
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Denver, Colorado • Kansas City, Kansas • Lebanon, New Hampshire + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed No phase listed Observational

The Sinonasal Cavity as a Reservoir for Upper Airway Bacterial Development

NCT03016689
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
7 Days to 3 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting No phase listed Observational

PKD Clinical and Translational Core Study

NCT01873235
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Results available

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

NCT04043806
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
46
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?

NCT02310789
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%, Macroduct sweat stimulator
Drug · Device
Lead sponsor
Richard Barry Moss
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Jul 21, 2026, 11:09 AM EDT
Not listed Not applicable Interventional

Gastrointestinal Microbiome Study of Appendiceal Cancer

NCT02599116
View directory record Official record
Conditions
Pseudomyxoma Peritonei, Appendiceal Neoplasm, Cancer, Appendiceal
Interventions
Bio-specimen collection, Questionnaire
Other
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Jul 21, 2026, 11:09 AM EDT
Not listed No phase listed Observational

Cystic Fibrosis Reproductive and Sexual Health Collaborative: Building Online Research Partnerships

NCT04999865
View directory record Official record
Conditions
Cystic Fibrosis, Patient Engagement
Interventions
4-part educational program to build patient-engagement methodology capacity
Other
Lead sponsor
University of Washington
Other
Eligibility
Not listed
Enrollment
100 participants
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

NCT00010452
View directory record Official record
Conditions
Lymphatic Malformations
Interventions
picibanil
Drug
Lead sponsor
University of Iowa
Other
Eligibility
6 Months to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Not applicable Interventional

Vitamin D and Microbiota in Cystic Fibrosis

NCT02589444
View directory record Official record
Conditions
Vitamin D Deficiency, Cystic Fibrosis
Interventions
High-Dose Vitamin D3, Stool Sample, Sputum Sample, Sham Comparator, Blood draw
Dietary Supplement · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

NCT04058366
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
33
States / cities
Tucson, Arizona • Long Beach, California • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors

NCT00002754
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Melanoma (Skin), Metastatic Cancer
Interventions
monoclonal antibody Me1-14 F(ab')2
Biological
Lead sponsor
Duke University
Other
Eligibility
3 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Phase 2 Interventional

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

NCT06582875
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney, Obesity
Interventions
Tirzepatide, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2025 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation

NCT02514473
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, Placebo, VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2017 · Synced Jul 21, 2026, 11:09 AM EDT
Active, not recruiting Not applicable Interventional

Renal Oxygen Consumption, Insulin Sensitivity, and Daily Caloric Restriction in ADPKD

NCT06496542
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney
Interventions
Daily caloric restriction, Standard advice control
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

Amiloride Solution and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis

NCT00547053
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Amiloride Solution for Inhalation
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Jul 21, 2026, 11:09 AM EDT
Terminated Phase 1 Interventional

Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers

NCT03680560
View directory record Official record
Conditions
Solid Tumor, HER-2 Protein Overexpression
Interventions
ACTR T Cell Product, Trastuzumab
Biological · Drug
Lead sponsor
Cogent Biosciences, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
New Haven, Connecticut • Miami, Florida • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Jul 21, 2026, 11:09 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

NCT00581360
View directory record Official record
Conditions
Adenoid Cystic Carcinoma
Interventions
doxorubicin and bortezomib
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
21
States / cities
Steubenville, Ohio • Beaver, Pennsylvania • Clairton, Pennsylvania + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2016 · Synced Jul 21, 2026, 11:09 AM EDT
Recruiting Not applicable Interventional

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

NCT07454174
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Ren-Nu and KetoCitra
Dietary Supplement
Lead sponsor
Richard Fatica
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Jul 21, 2026, 11:09 AM EDT